Properties (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
Vonicog alfa
|
| gptkbp:administrativeDivision |
as needed
|
| gptkbp:clinicalTrials |
gptkb:National_Hemophilia_Foundation
gptkb:American_Society_of_Hematology Phase 1 Phase 2 Phase 3 NCT02212345 hemophilia_treatment |
| gptkbp:contraindication |
urticaria
anaphylaxis thrombocytopenia hypotension hypersensitivity to components active thromboembolic disease |
| gptkbp:date |
2018-12-14
|
| gptkbp:dosageForm |
lyophilized powder for reconstitution
|
| gptkbp:firstAppearance |
gptkb:FDA
|
| gptkbp:formulation |
recombinant von Willebrand factor
|
| gptkbp:hasPopulation |
adults
pediatric patients |
| gptkbp:healthcare |
potential side effects
importance of follow-up care proper administration techniques recognition of bleeding symptoms |
| https://www.w3.org/2000/01/rdf-schema#label |
Vonvendi
|
| gptkbp:is_monitored_by |
clinical response
factor levels |
| gptkbp:isSubjectTo |
50 mL
|
| gptkbp:mandates |
prevention of bleeding episodes
surgical_procedures_in_patients_with_von_Willebrand_disease |
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:packaging |
single-use vial
|
| gptkbp:patentStatus |
exclusive rights
patented |
| gptkbp:regulatoryCompliance |
FDA_approved
EMA_approved Health_Canada_approved |
| gptkbp:researchInterest |
long-term safety
comparative effectiveness efficacy in children |
| gptkbp:route |
intravenous
|
| gptkbp:sideEffect |
headache
nausea fever rash thrombosis |
| gptkbp:storage |
store at 2°C to 8°C
|
| gptkbp:supplyChain |
cold chain logistics
specialized distributors |
| gptkbp:usedFor |
treatment_of_von_Willebrand_disease
|